Reporter brief
Effect of Mammalian Target of Rapamycin Inhibition and Other Metabolism Modulating Interventions on the Elderly: Immune, Cognitive, and Functional Consequences
What happened
Trial registry update: COMPLETED. Results are posted in the registry; assessment pending.
Why it matters
Assessment pending; this report does not establish a change in evidence.
What it does NOT prove
- The abstract provides no efficacy or safety results from the human trial, only study rationale and design
- Preclinical benefits in mice do not establish that rapamycin produces similar effects in elderly humans
- Without reported outcomes, this abstract alone cannot demonstrate whether rapamycin improves immune response, cognition, or function in the target population
Study design and sample
Rct; Human.
Elderly persons aged 70-95
- Design
- Rct
- Sample
- —
- Journal
- The University of Texas Health Science Center at San Antonio
- Published
- Dec 4, 2018
Effect size
Not recorded.
Caveats
- Assessment: Unassessed.
- Only the source material recorded on this evidence page was assessed.
Conflicts and funding
Not recorded.
Previous evidence
See the Rapamycin timeline and recorded assessment for prior evidence.
Primary source
Cancel Death charts and briefs may be reproduced editorially with attribution to CancelDeath.com. This brief is generated from the primary recorded source facts and assessment. Its review status is shown below; verify quotations against the paper before publication.